Legal & General Group Plc trimmed its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 14.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,758 shares of the medical equipment provider's stock after selling 26,654 shares during the quarter. Legal & General Group Plc owned 0.15% of NovoCure worth $4,701,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the stock. Lindbrook Capital LLC grew its position in shares of NovoCure by 189.2% during the fourth quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider's stock worth $55,000 after buying an additional 1,213 shares in the last quarter. Blue Trust Inc. increased its position in shares of NovoCure by 70.7% in the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider's stock valued at $56,000 after purchasing an additional 781 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of NovoCure in the 4th quarter valued at $70,000. Versant Capital Management Inc raised its holdings in shares of NovoCure by 35.8% in the 4th quarter. Versant Capital Management Inc now owns 3,341 shares of the medical equipment provider's stock valued at $100,000 after purchasing an additional 880 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of NovoCure by 57.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider's stock worth $129,000 after purchasing an additional 1,575 shares during the last quarter. Hedge funds and other institutional investors own 84.61% of the company's stock.
NovoCure Stock Performance
Shares of NVCR traded up $0.18 during mid-day trading on Friday, reaching $18.73. 551,141 shares of the company's stock were exchanged, compared to its average volume of 1,182,285. The business's fifty day simple moving average is $18.55 and its 200-day simple moving average is $21.60. The stock has a market capitalization of $2.09 billion, a PE ratio of -13.38 and a beta of 0.65. NovoCure Limited has a 52-week low of $11.88 and a 52-week high of $34.13. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44.
NovoCure (NASDAQ:NVCR - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.16. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The company had revenue of $154.99 million for the quarter, compared to the consensus estimate of $147.57 million. On average, equities research analysts expect that NovoCure Limited will post -1.3 earnings per share for the current year.
Wall Street Analysts Forecast Growth
NVCR has been the topic of several recent analyst reports. StockNews.com lowered NovoCure from a "hold" rating to a "sell" rating in a report on Friday. Wedbush cut their target price on NovoCure from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 16th. HC Wainwright restated a "buy" rating and set a $38.00 target price on shares of NovoCure in a research note on Tuesday, January 14th. JPMorgan Chase & Co. cut their price objective on shares of NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, Piper Sandler lowered their target price on shares of NovoCure from $42.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, NovoCure has an average rating of "Hold" and a consensus price target of $32.83.
Check Out Our Latest Stock Analysis on NVCR
NovoCure Profile
(
Free Report)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
Recommended Stories
Before you consider NovoCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovoCure wasn't on the list.
While NovoCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
